Compugen Ltd
Research Compugen Ltd (CGEN) on Bullrun: market cap USD 201.76M, P/E 5.7. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCGEN
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 201.76M
- P/E5.7
- Financial periodQ2 2026
- RevenueUSD 2.60M
- Net income-USD 7.01M
- Gross margin-3.5%
Valuation Snapshot
latest market cap is USD 201.76M; P/E is 5.7.
Peer valuation comparison
Latest P/E is 5.75x versus a Healthcare sector median of 24.61x (76.6% below).
Latest P/E is 5.75x versus a Israel median of 24.85x (76.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 72.76M | USD 35.34M | USD 31.33M | 87.3% | 0.38 | USD 90.60M | USD 2.96M | USD 102.73M |
| FY2024 | USD 27.86M | -USD 14.23M | USD 49.49M | 71.5% | -0.16 | USD 18.23M | USD 2.91M | USD 54.91M |
| FY2023 | USD 33.46M | -USD 18.75M | -USD 36.06M | 94.0% | -0.21 | USD 13.89M | USD 1.35M | USD 65.56M |
| FY2022 | USD 7.50M | -USD 33.69M | -USD 34.59M | 87.0% | -0.39 | USD 11.06M | USD 1.93M | USD 77.68M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 201.76M | 5.7 | n/a | n/a |
| 2025 | 2025-12-31 | USD 144.67M | 4.1 | n/a | n/a |
| 2024 | 2024-12-31 | USD 137.00M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 174.89M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 62.37M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 371.66M | n/a | n/a | n/a |
About Compugen Ltd
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe. The company's pipeline consists of COM701, an immuno-oncology pipeline program with an anti-PVRIG antibody;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Compugen Ltd's market cap?
Compugen Ltd's market capitalization is USD 201.76M.
What is Compugen Ltd's P/E ratio?
Compugen Ltd's price-to-earnings (P/E) ratio is 5.7.
What does Compugen Ltd do?
Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.